IntroductIon: the effect of statins on the levels of cell adhesion molecules (CAM) is discussed in the literature as one of the pleiotropic effects of the drugs. This effect is one of the ways that could be used to control the initial stage of atherogenesis. The research in this field is inadequate and controversial. Prevention guidelines recommend that target levels of ldl cholesterol in high-risk patients should be less than 2.6 mmol/l. If the primary target is ldl-cholesterol, it is doubtful if patients can have any significant changes in the levels of the cell adhesion molecules (caM). AIm: Study the effect of simvastatin administered in a moderate dose of 40 mg and in a high dose of 80 mg on endothelium activation in the context of the plasma levels of soluble cellular adhesion molecules (sIcaM-1, svcaM-1, se-selectin, sP-selectin) in recently diagnosed untreated severe hypercholesterolemia after reaching target levels for the ldlcholesterol below 2.6 mmol/l. PAtIents And methods: One hundred patients (aged > 16 years) were included in the study. hypercholesterolemia was defined as fasting total serum cholesterol level greater than 7.5 mmol/l and ldl-cholesterol > 4.9 mmol/l. The study was carried out in three phases, the main goal being titration of simvastatin dose from 40 to 80 mg with the purpose of achieving the target ldl level of < 2.6 mmol/l in a randomised placebo-controlled study. results: There was a statistically significant reduction of svcaM-1 following the 80-mg simvastatin therapy for one month after reaching target levels of ldl-cholesterol < 2.6 mmol/l in hypercholesterolemic patients in comparison with the moderate dose (40 mg) of simvastatin for one month (p < 0.001). The results of the study demonstrated that simvastatin in a dose of 80 mg exerted an effect on the levels of some caM, and particularly on vcaM-1 in contrast to the same drug used in a dose of 40 mg . conclusIon: as different statins most likely have a distinctly specific effect on different adhesion molecules, this study seeks to establish a suitable panel of such adhesion molecules that may be used in monitoring statin therapy.
International recommendations for management of hypercholesterolemia underscore the importance of diagnosis and treatment of asymptomatic individuals with high absolute cardiovascular risk. Individuals with marked hypercholesterolemia fall into this group as well. [1] [2] [3] On the other hand, in the context of the inflammatory genesis of the atherosclerosis the inflammatory reaction begins with the trundle of mononuclear cells on the endothelium followed by their adhesion, activation and transmigration to the sub-endothelium. The interaction between the leucocytes, the leucocytes and the endothelium, and between the leucocytes and the extracellular matrix is mediated by so called cell adhesion molecules (CAM). [4] [5] [6] [7] [8] These molecules play a highly signifi- The mononuclear cell engaged in the intima of the large and medium blood vessels is exactly the first step in the beginning of ateroslerosis. [4] [5] [6] [7] [8] This makes the uptake of leucocytes from the capillaries to be more precise and multiple.
Clinical Investigations

ORIgInal aRtIclES
Still, there are many ambiguous questions regarding the place of CAM in blood vessel pathology. [4] [5] [6] [7] [8] Data on circulating CAM supports the thesis that they are potential atherosclerosis biomarkers. There is ample evidence that soluble intracellular cell adhesion molecules (sICAM-1) are highly informative in myocardial infarctions. 4 Patients diagnosed with chronic ischemic heart disease have significantly higher levels of sVCAM-1 and E-selectin than healthy subjects. 6 In Bulgaria there are data about the levels of sVCAM-1 and sICAM-1 in patients with hypercholesterolemia, but it is sVCAM-1 only that have been found to be statistically different in comparison with controls. 9 Statins have been demonstrated to be effective as lipid lowering agents -they can slow down and/or stop atherosclerotic plaque formation. 10 The latter is likely to be partly due to their pleiotropic effects. The effect of statins on CAM levels is discussed in the literature as one of the pleiotropic effects of the drugs. This effect is one possible mechanism that could be used to control the initial stage of atherogenesis. The research in this field is inadequate and controversial. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Prevention guidelines recommend that target levels of LDL cholesterol in high-risk patients should be less than 2.6 mmol/l. If the primary target is LDL-cholesterol, it is doubtful if patients can have any significant changes in CAM levels. This is the primary issue discussed in this article.
AIM
Study the effect of simvastatin used in a moderate dose of 40 mg and in a high dose of 80 mg on the endothelium activation in the context of the plasma levels of soluble cellular adhesion molecules (sICAM-1, sVCAM-1, sE-selectin, sP-selectin) in recently diagnosed untreated severe hypercholesterolemia after reaching target levels of LDL-cholesterol below 2.6 mmol/l.
PaTIenTS
Between June 2006 and September 2008 we examined 460 outpatients with primary hypercholesterolemia in the Preventive Cardiology Surgery of the Clinic of Cardiology with St George University Hospital in Plovdiv. One hundred of these patients were included in the study; the patients were over 16 years of age. Hypercholesterolemia was defined as fasting total serum cholesterol level greater than 8.5 mmol/l and LDL-cholesterol below 5.9 mmol/l. All patients had a family history of atherosclerotic disease. All known endothelial function-related conditions and drugs were included in the exclusion criteria. The use of antioxidants as exclusion criteria is in context of the fasting condition of the patients 12 hours before examination. None of the patients had been taking lipid-lowering medication prior to the study.
The exclusion criteria were: analyzer Konelab 60i (Thermo Electron Co, Vantaa, Finland). The intra-assay and inter assay coefficients of variation were calculated for Apo-A 1 -2.7% and 4.8%, respectively and Apo-B -1.6% and 3.1%, respectively. Reference values for Apo-A 1 : reference range 1.09-1.84 g/l for males, 1.06-2.28 g/l for females. Reference values for Apo-B: reference range 0.63-1.88 g/l for males, 0.56-1.82 g/l for females. The serum soluble intracellular adhesion molecules (sICAM-1), soluble vascular adhesion molecules (sVCAM-1), P-selectin and Е-selectin were determined by ELISA using kits from DLD Diagnostika GMBH (Hamburg, Germany) and BenderMed Systems (Vienna, Austria). The intra-and inter assay coefficients of variation were calculated (4.5-5.8% and 5.8-8.2%, respectively). Serum samples were obtained and stored as aliquots at -20°C until analysis was performed, up to two months. Grossly haemolysed or lipemic specimens were discarded. Prior to the assay frozen plasma was brought slowly to room temperature and mixed gently as required by the manifacture's instructions. Repeated freeze-twan cycles were avoided. Reference values and reference range for cell adhesion molecules were set at 128.9-374.5 ng/ml (sICAM-1), 170.4-478.4 (sVCAM-1), 9.15-65.19 (sE-selectin), and 101.7-209.7 (sP-selectin) for both males and females and for all age groups (older than 18 years).
Mediterranean diet was implemented for the entire duration of the study. Patients had not received statin therapy prior to the study. The study is a prospective follow-up trial conducted in three stages. The first stage includes determination of the group of patients reaching target levels with 40 mg simvastatin, compared to a placebo group. The reason we included a wash-out period was to create equal baseline conditions without therapy. After one-month wash-out the LDL-C levels were measured again -these levels are presented in LDL -low density lipoprotein cholesterol; ALT -alanine aminotransferase Table 5 (LDL-C levels at the end of month 2). According to literature there is a rebound of the lipid profile one week after therapy is discontinued. 10 Lipid profile becomes stable within a month, approaching baseline values, which was the reason we had a one-month wash-out.
Following initial laboratory and instrumental work-up all patients received 40 mg simvastatin once daily, at 9.00 p.m. This dose is recommended as initial in patients with severe hypercholesterolemia. The laboratory parameters -lipid profile, apolipoproteins, soluble intracellular adhesion molecules -were measured at baseline and at the end of month 1. Patients received simvastatin in the evening before the study for one month. The phase lasts one month as, according to literature data, it takes 3-4 weeks to achieve optimal blocking of the enzyme (HMG-CoA reductase) of the speed-determining stage of the cholesterol synthesis, i.е. optimal lipid-regulation. 10 Study design: 460 dyslipidemic patients were screened; 100 of these had severe hypercholesterolemia with total cholesterol level ≥ 7.5 mmol/l and LDL-C level ≥ 4.9 mmol/l meeting SimonBroom's criteria for clinical diagnosis of family hypercholesterolemia. The study was carried out in three phases, the main goal being the titration of simvastatin dose from 40 to 80 mg with the purpose of achieving the target LDL level of ≤ 2.6 mmol/l in a randomised placebo-controlled study. During phase 1 all patients were randomized into two groups: one group of 50 patients received 40 mg simvastatin in one single dose at bedtime, 09.00 p.m. (it is recommended as an initial dose in all patients with severe hypercholesterolemia) and the other 50 patients received placebo. Of all patients on 40 mg simvastatin 15 patients reached target LDL level of less than 2.6 mmol/l, and 30 did not reach target. During phase 2 we discontinued the statin therapy for 1 month (at the end of month 1 to the end of month 2) in all patients who had not reached target LDL-C level of ≤ 2.6 mmol/l -washout period. During phase 3 all the patients (n = 30) who had not reached target LDL-C level of ≤ 2.6 mmol/l during phase 1 were randomized in two groups -one of them received 80 mg simvastatin, the other received placebo for a month (Fig. 1) . Results are presented as mean ± SD, unless otherwise stated.
Results
Therapeutic algorithm (phase 1 of the study).
Baseline characteristics of the examined hypercholesterolemic subjects and placebo group are presented in Table 1 . There was no statistically significant difference between the examined hypercholesterolemic subjects and the placebo group for There was statistically significant reduction of total cholesterol, triglyceride, LDL-C, Apo-B and Apo-B/Apo-A 1 levels, sICAM-1, sVCAM-1, sEselectin, sP-selectin and an increase of HDL-C and Apo-A 1 levels following 40-mg-simvastatin therapy for one month in comparison with the placebo group (p < 0.001) ( Table 2 ). Fifteen patients reached the target LDL-C level of ≤ 2.6 mmol/l with 40 mg of simvastatin, 3 patients were found to have a critical increase level of ALT ≥ 3 times, 2 patients resigned from the study, 30 patients did not attain the target LDL-C level of ≤ 2.6 mmol/l. 2. Therapeutic algorithm -phase 2 of the studywashout period for all 30 patients not reaching the target LDL-C level of ≤ 2.6 mmol/l (Fig. 1) . 3. Therapeutic algorithm -phase 3 of the study: There was a statistically significant reduction in total cholesterol, triglyceride, LDL-C, Apo-B and Apo-B/Apo-A 1 levels, sICAM-1, sVCAM-1, sEselectin, sP-selectin and an increase in HDL-C, Apo-A 1 following 80-mg-simvastatin therapy for one month in comparison with the placebo group (p < 0.001) (Tables 3, 4) . Eleven patients reached the target LDL-C level of ≤ 2.6 mmol/l with 80 mg of simvastatin, two patients had a critical increase of the ALT level ≥ 3 times, 2 patients did not attain the target LDL-C level of ≤ 2.6 mmol/l: the alternative is change of statin.
dIsCussIon
The results of the study suggest that 80 mg of simvastatin exerts an effect on the levels of some CAM, and particularly on VCAM-1 and sICAM in contrast to the moderate dose of 40 mg of simvastatin. In the literature the latter two are closely connected with the presence of stable atherosclerotic plaque which is the context of the examined patients with asymptotic severe untreated hypercholesterolemia. 6 The effect of simvastatin on VCAM-1 is a form of expression of the drug's pleiotropic effect. Most of the literature sources that report of the effect of various statins on CAM levels are similar and determine their activity. [11] [12] [13] [16] [17] [18] [19] [20] The positive effect in the present study obtained only with 80 mg of simvastatin on CAM in contrast to the effect achieved with 40 mg accounts for the fact that higher doses of statins can have a positive effect on cardiovascular events i.e. aggressive statin therapy versus therapy with moderate doses of the drugs.
Statins vary in their pharmacokinetics and pharmacodynamics. Their lipid regulating and pleiotropic effect are different as well. 10 Therefore, data on simvastatin cannot be used for other statins. A previous study demonstrated that patients with asymptotic hypercholesterolemia treated with 20 mg pravastatin for 24h reduced sVCAM-1 and sICAM-1 to such levels as in the reference interval for these parameters. 11 Pravastatin has been shown to possess a significant pleiotropic effects in contrast to other statins. As different statins most likely have a distinctly specific effect on different adhesion molecules, this study contributes to establishing a suitable panel of such adhesion molecules that may be used in monitoring statin therapy.
Administration of high simvastatin doses should be done with caution. Close monitoring of patients is important in the course of therapy. 21, 22 As there is a risk of drug interactions at cytochrome P450 3A4 level in the liver and increased simvastatin levels, other drugs, influencing the same enzyme levels, should be taken into consideration. According to the Food and Drug Administration control examinations should be carried out every 3 months and every 6 months during therapy. 21, 22 Rezaie-Majd et al. 23 studied the in vivo effects of simvastatin therapy in hypercholesterolemia patients on the expression of ICAM-1 in vitro. They had two groups of patients: one group received 20 mg and the other group was treated with 40 mg per day. After 6 weeks of treatment the surface expression of ICAM-1 and his ligand from the integrin group over the peripheral monocytes lowered significantly in both groups of patients, The positive effect of the therapy with simvastatin, atorvastatin and simvastatin on the serum level of different CAM in patients with hypercholesterolemia and clinical manifestation of atherosclerosis is confirmed by other authors too. 23 M. Sardo et al. 15 , however, studied the effect of simvastatin on sICAM-1 and sE-selectin in patients with hypercholesterolemia without other risk factors for atherosclerosis and found no significant reduction of the levels of sICAM and sE-selectin after a 4-week therapy.
Jilma et al. 24 reported similar data in 2003 about the effect of 3-month treatment with atorvastatin, simvastatin and pravastatin on the levels of sICAM-1, sVCAM-1 and sE-selectin in 75 patients with moderate hypercholesterolemia. They found that the level of the examined CAM did not decrease even in patients with 50% reduction of the LDL-cholesterol. This result is in context of our LDL-target for all patients, i.e. optimal lipid regulation is basic for another statin's effect.
ConClusIons
When LDL-cholesterol ≤ 2.6 mmol/l is targeted in patients with newly diagnosed untreated severe hypercholesterolemia by receiving 80 mg of simvastatin, only the levels of VCAM-1 lower considerably and significantly. In contrast, patients reaching this target with 40 mg simvastatin do not affect CAM. With the accumulation of more experimental results by methodologically similar research and meta analysis it could be possible to get a clear idea to what extent CAM can be used as an effective marker in therapeutic regulation of the disturbed endothelium function with statins in hypercholesterolemia.
